<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204499</url>
  </required_header>
  <id_info>
    <org_study_id>21919</org_study_id>
    <nct_id>NCT04204499</nct_id>
  </id_info>
  <brief_title>Analysis of Screen-detected Lung Cancers' Genomic Traits</brief_title>
  <acronym>ASCENT</acronym>
  <official_title>Analysis of Screen-detected Lung Cancers' Genomic Traits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, observational cohort study of patients undergoing surgical resection for low&#xD;
      dose CT (LDCT) screen-detected lung cancer (detected through the SUMMIT study -&#xD;
      ClinicalTrials.gov Identifier: NCT03934866), in which translational research is a fundamental&#xD;
      aspect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ASCENT study seeks to examine the genomic signatures of screen-detected cancers, in order&#xD;
      to categorise the biological behaviour of such lesions and correlate this against&#xD;
      non-invasive biological and radiological parameters. From these data, the plan is to explore&#xD;
      strategies to characterise LDCT-detected cancers through non-invasive means, which the&#xD;
      researchers believe may prove key in mitigating potential screening-associated harms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genomic exploratory research</measure>
    <time_frame>3 years</time_frame>
    <description>Measuring the differences in chromosomal instability between fast- and slow-growing screen detected cancers, quantified by weighted genome integrity index (WGII) derived from whole exome sequencing (WES) data</description>
  </primary_outcome>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Lung Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood collection will take place from consented patients at the time of anaesthetic induction&#xD;
      pre-surgery, to include:&#xD;
&#xD;
        -  4 x 10ml Streck tubes for germline DNA and exploratory biomarker analyses&#xD;
&#xD;
        -  Tumour surplus to diagnostic and pathological requirements will be collected for whole&#xD;
           exome sequencing.&#xD;
&#xD;
        -  Archival Diagnostic FFPE blocks.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Screen detected lung cancer patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with confirmed lung cancer or probable lung cancer via LDCT-screening as&#xD;
             part of the SUMMIT study.&#xD;
&#xD;
          2. Planned for, or completed primary surgical resection either for histologically&#xD;
             confirmed lung cancer, or strongly suspected lung cancer.&#xD;
&#xD;
          3. Able to provide written informed consent (or verbal informed consent for participants&#xD;
             consenting to retrospective diagnostic samples and data collection only).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with neoadjuvant therapy for current lung malignancy as per local MDT&#xD;
             treatment decision.&#xD;
&#xD;
          2. Known Active Human Immunodeficiency Virus (HIV), Hepatitis B virus, Hepatitis C Virus&#xD;
             or Syphilis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>77 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Janes</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Hughes</last_name>
    <phone>0207 679 9284</phone>
    <email>ctc.ascent@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan Teague</last_name>
    <phone>0207 679 9891</phone>
    <email>ctc.ascent@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Bart's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Dr Hall</last_name>
      <email>h.hall@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Will Dr Ricketts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLH</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Dr Hall</last_name>
      <email>h.hall@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Sam Prof Janes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genomic signatures</keyword>
  <keyword>Screen-detected cancer</keyword>
  <keyword>Non-invasive biological and radiological parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

